共 190 条
[11]
Maschmeyer G(2021)Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer Pharmazie 76 450-1085
[12]
Aapro M(2013)Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients J Natl Cancer Inst 105 1078-411
[13]
Cooper KL(2009)Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States Curr Med Res Opin 25 401-4214
[14]
Madan J(2016)Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (Nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy PLoS ONE 11 4198-3167
[15]
Whyte S(2005)Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials J Clin Oncol 23 3158-1900
[16]
Stevenson MD(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 1892-e203
[17]
Akehurst RL(2019)Dynamic changes of health utility in lung cancer patients receiving different treatments: a 7-year follow-up J Thorac Oncol 14 e195-4831
[18]
Garon EB(2017)Health state utilities in non-small cell lung cancer: an international study Asia Pac J Clin Oncol 13 84-18
[19]
Ciuleanu TE(2008)Health state utilities for non small cell lung cancer Health Qual Life Outcomes 6 4825-e169
[20]
Arrieta O(2020)Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study Support Care Cancer 28 8-332